Why did Teva ink an $85M deal to sidestep the Oklahoma opioid trial?

Less than 48 hours before the first major opioid trial began, Teva struck an $85 million deal with Oklahoma officials, about one-third what painkiller giant Purdue Pharma paid to settle similar claims.

That leaves Johnson & Johnson as the only remaining drugmaker facing trial Tuesday, while Teva can breathe a sigh of relief—at least until a much bigger legal fight plays out this fall.